Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by den Broeder, A. A.
Right arrow Articles by van Riel, P. L. C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by den Broeder, A. A.
Right arrow Articles by van Riel, P. L. C. M.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2002; 41: 638-642
© 2002 British Society for Rheumatology

Original Papers

Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-{alpha}

A. A. den Broeder, M. C. W. Creemers, A. M. van Gestel and P. L. C. M. van Riel

Department of Rheumatology, University Medical Center St Radboud, Nijmegen, PO Box 9101, 6500 HB, The Netherlands

Objective. Anti-tumour necrosis factor {alpha} (TNF-{alpha}) therapy yields high response rates shortly after institution of therapy in patients with rheumatoid arthritis (RA), and on theoretical grounds large differences in the effective dose between patients can be expected. Together with the high costs, these differences warrant new approaches to the way patients are dosed.

Methods. We used the Disease Activity Score (DAS28), a composite disease activity index, to titrate the dose of anti-TNF-{alpha} (adalimumab, D2E7; Knoll) in 21 patients with low disease activity in an open extension study lasting 40 weeks. The dose of anti-TNF-{alpha} was reduced stepwise and dosing intervals were kept stable. Disease activity and flares were assessed using the DAS28. Patients who flared received the previous effective dose.

Results. Dose reduction was accomplished in 15 patients. The total amount of anti-TNF-{alpha} given to the patients was reduced by 67%. At the end of the study the mean DAS28 had not changed and no patients dropped out because of persistent worsening of the RA.

Conclusion. Dose titration of anti-TNF-{alpha} treatment using the DAS28 is feasible and leads to overall dose reduction while maintaining clinical efficacy. This approach will save costs and possibly prevent long-term side-effects.

KEY WORDS: DAS28, Anti-TNF-{alpha}, Dose titration, RA, Adalimumab, Infliximab.

Correspondence to: M. C. W. Creemers.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
C. O. BINGHAM III, C. POHL, T. G. WOODWORTH, S. E. HEWLETT, J. E. MAY, M. U. RAHMAN, J. P. WITTER, D. E. FURST, C. V. STRAND, M. BOERS, et al.
Developing a Standardized Definition for Disease "Flare" in Rheumatoid Arthritis (OMERACT 9 Special Interest Group)
J Rheumatol, October 1, 2009; 36(10): 2335 - 2341.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
B J F van den Bemt, A A den Broeder, G F Snijders, Y A Hekster, P L C M van Riel, B Benraad, G J Wolbink, and F H J van den Hoogen
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
Ann Rheum Dis, December 1, 2008; 67(12): 1697 - 1701.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. C. Greenwood, J. Rathi, A. J. Hakim, D. L. Scott, and D. V. Doyle
Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-{alpha} inhibitors in adults with rheumatoid arthritis
Rheumatology, July 1, 2007; 46(7): 1165 - 1167.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
M. Flendrie, M. C. W. Creemers, and P. L. C. M. van Riel
Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns
Rheumatology, January 1, 2007; 46(1): 146 - 149.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
J. Ledingham, C. Deighton, and on behalf of the British Society for Rheumatology
Update on the British Society for Rheumatology guidelines for prescribing TNF{alpha} blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001)
Rheumatology, February 1, 2005; 44(2): 157 - 163.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. L. Scott, C. Antoni, E. H. Choy, and P. C. L. M. van Riel
Joint counts in routine practice
Rheumatology, August 1, 2003; 42(8): 919 - 923.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.